We got an exclusive look inside Moderna’s labs, where the biotech upstart is planning what comes after its blockbuster coronavirus vaccine

• Led by its coronavirus vaccine, Moderna has surged into the drug industry’s top ranks.
• The biotech has rapidly expanded to boost production by hiring hundreds and opening new buildings.
• Insider visited Moderna’s labs to learn about the biotech’s plans beyond COVID-19.

NORWOOD, Massachusetts – Moderna’s swagger is impossible to miss.

In the main lobby of the biotech’s sprawling campus in the Boston suburbs, baskets are filled with pins touting the company’s milestones: delivering 100 million and then 200 million doses of its coronavirus vaccine. With Moderna aiming to deliver up to 1 billion doses by year’s end, it seems inevitable the pins will turn into Girl Scout-like strings of badges soon enough.

Some employees walk around in T-shirts styled like the sitcom “Friends” with a company-centric episode title: “The one where Moderna delivered 100 million doses.”